NR 566 / NR566 Advanced
Pharmacology Care of the Family
Midterm Review Actual Exam 2026/2027
– Complete Exam-Style Questions |
Detailed Rationales – Pass Guaranteed –
A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions
1-10)
Q1. A drug with high first-pass metabolism is best administered via
which route to achieve systemic effect?
• A) Oral
• B) Sublingual
• C) Intravenous
• D) Rectal
Correct ,,,answer,,,,: C) Intravenous
Rationale: IV administration completely bypasses first-pass metabolism
in the liver. Sublingual and rectal routes avoid it partially, but IV is the
most reliable route for drugs with extensive first-pass hepatic
metabolism .
,Q2. Which cytochrome P450 enzyme is most commonly involved in
clinically significant drug interactions?
• A) CYP1A2
• B) CYP2C9
• C) CYP3A4
• D) CYP2E1
Correct ,,,answer,,,,: C) CYP3A4
Rationale: CYP3A4 metabolizes over 50% of all drugs, including statins,
benzodiazepines, calcium channel blockers, and many antifungals. It is
the most frequent site of clinically significant drug-drug interactions .
Q3. A patient develops an exaggerated response to warfarin after
starting amiodarone. This interaction is due to:
• A) Increased renal excretion of warfarin
• B) P-glycoprotein induction
• C) CYP2C9 inhibition by amiodarone
• D) Plasma protein binding displacement
Correct ,,,answer,,,,: C) CYP2C9 inhibition by amiodarone
Rationale: Amiodarone inhibits CYP2C9, the enzyme responsible for
warfarin metabolism. This leads to increased warfarin levels, elevated
INR, and bleeding risk. INR monitoring and dose adjustment are required
when amiodarone is initiated or discontinued .
Q4. Which statement best describes a "prodrug"?
• A) An active drug that requires no metabolism
• B) An inactive compound converted to an active metabolite in vivo
• C) A drug that irreversibly binds to receptors
, • D) A drug excreted unchanged in the urine
Correct ,,,answer,,,,: B) An inactive compound converted to an active
metabolite in vivo
Rationale: Prodrugs such as clopidogrel, enalapril, and valacyclovir
require hepatic or tissue activation to become therapeutically active. This
design can improve bioavailability or reduce side effects .
Q5. A drug with a narrow therapeutic index (NTI) requires:
• A) Once-daily dosing only
• B) Therapeutic drug monitoring
• C) High protein binding
• D) Renal adjustment in all patients
Correct ,,,answer,,,,: B) Therapeutic drug monitoring
Rationale: NTI drugs—including lithium, warfarin, phenytoin, and
digoxin—have a small margin between therapeutic efficacy and toxicity.
Serum levels must be monitored to avoid subtherapeutic dosing or
adverse events .
Q6. Which factor most increases drug half-life in older adults?
• A) Increased hepatic blood flow
• B) Increased lean body mass
• C) Decreased renal clearance
• D) Increased albumin levels
Correct ,,,answer,,,,: C) Decreased renal clearance
Rationale: Age-related decline in glomerular filtration rate (GFR) prolongs
the half-life of renally cleared drugs such as digoxin, metformin, and many
, antibiotics. Dose adjustment based on creatinine clearance is essential in
elderly patients .
Q7. Grapefruit juice increases levels of certain statins by inhibiting:
• A) Intestinal CYP3A4
• B) Hepatic CYP2D6
• C) Renal OAT transporters
• D) P-glycoprotein only
Correct ,,,answer,,,,: A) Intestinal CYP3A4
Rationale: Grapefruit juice inhibits intestinal CYP3A4, increasing the
bioavailability of atorvastatin and simvastatin. This raises the risk of
myopathy and rhabdomyolysis. Patients should avoid grapefruit products
while taking these statins .
Q8. The volume of distribution (Vd) is high for a drug that is:
• A) Highly water-soluble
• B) Highly lipophilic
• C) Highly protein-bound in plasma
• D) Restricted to the vascular compartment
Correct ,,,answer,,,,: B) Highly lipophilic
Rationale: Lipophilic drugs (e.g., diazepam, amiodarone) readily cross
cell membranes and distribute into adipose and other tissues, resulting in
a high Vd. This prolongs elimination half-life and may require loading
doses .
Q9. A patient with hepatic impairment is prescribed a drug metabolized
by CYP2C19. The PMHNP should anticipate:
• A) Decreased drug half-life
Pharmacology Care of the Family
Midterm Review Actual Exam 2026/2027
– Complete Exam-Style Questions |
Detailed Rationales – Pass Guaranteed –
A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions
1-10)
Q1. A drug with high first-pass metabolism is best administered via
which route to achieve systemic effect?
• A) Oral
• B) Sublingual
• C) Intravenous
• D) Rectal
Correct ,,,answer,,,,: C) Intravenous
Rationale: IV administration completely bypasses first-pass metabolism
in the liver. Sublingual and rectal routes avoid it partially, but IV is the
most reliable route for drugs with extensive first-pass hepatic
metabolism .
,Q2. Which cytochrome P450 enzyme is most commonly involved in
clinically significant drug interactions?
• A) CYP1A2
• B) CYP2C9
• C) CYP3A4
• D) CYP2E1
Correct ,,,answer,,,,: C) CYP3A4
Rationale: CYP3A4 metabolizes over 50% of all drugs, including statins,
benzodiazepines, calcium channel blockers, and many antifungals. It is
the most frequent site of clinically significant drug-drug interactions .
Q3. A patient develops an exaggerated response to warfarin after
starting amiodarone. This interaction is due to:
• A) Increased renal excretion of warfarin
• B) P-glycoprotein induction
• C) CYP2C9 inhibition by amiodarone
• D) Plasma protein binding displacement
Correct ,,,answer,,,,: C) CYP2C9 inhibition by amiodarone
Rationale: Amiodarone inhibits CYP2C9, the enzyme responsible for
warfarin metabolism. This leads to increased warfarin levels, elevated
INR, and bleeding risk. INR monitoring and dose adjustment are required
when amiodarone is initiated or discontinued .
Q4. Which statement best describes a "prodrug"?
• A) An active drug that requires no metabolism
• B) An inactive compound converted to an active metabolite in vivo
• C) A drug that irreversibly binds to receptors
, • D) A drug excreted unchanged in the urine
Correct ,,,answer,,,,: B) An inactive compound converted to an active
metabolite in vivo
Rationale: Prodrugs such as clopidogrel, enalapril, and valacyclovir
require hepatic or tissue activation to become therapeutically active. This
design can improve bioavailability or reduce side effects .
Q5. A drug with a narrow therapeutic index (NTI) requires:
• A) Once-daily dosing only
• B) Therapeutic drug monitoring
• C) High protein binding
• D) Renal adjustment in all patients
Correct ,,,answer,,,,: B) Therapeutic drug monitoring
Rationale: NTI drugs—including lithium, warfarin, phenytoin, and
digoxin—have a small margin between therapeutic efficacy and toxicity.
Serum levels must be monitored to avoid subtherapeutic dosing or
adverse events .
Q6. Which factor most increases drug half-life in older adults?
• A) Increased hepatic blood flow
• B) Increased lean body mass
• C) Decreased renal clearance
• D) Increased albumin levels
Correct ,,,answer,,,,: C) Decreased renal clearance
Rationale: Age-related decline in glomerular filtration rate (GFR) prolongs
the half-life of renally cleared drugs such as digoxin, metformin, and many
, antibiotics. Dose adjustment based on creatinine clearance is essential in
elderly patients .
Q7. Grapefruit juice increases levels of certain statins by inhibiting:
• A) Intestinal CYP3A4
• B) Hepatic CYP2D6
• C) Renal OAT transporters
• D) P-glycoprotein only
Correct ,,,answer,,,,: A) Intestinal CYP3A4
Rationale: Grapefruit juice inhibits intestinal CYP3A4, increasing the
bioavailability of atorvastatin and simvastatin. This raises the risk of
myopathy and rhabdomyolysis. Patients should avoid grapefruit products
while taking these statins .
Q8. The volume of distribution (Vd) is high for a drug that is:
• A) Highly water-soluble
• B) Highly lipophilic
• C) Highly protein-bound in plasma
• D) Restricted to the vascular compartment
Correct ,,,answer,,,,: B) Highly lipophilic
Rationale: Lipophilic drugs (e.g., diazepam, amiodarone) readily cross
cell membranes and distribute into adipose and other tissues, resulting in
a high Vd. This prolongs elimination half-life and may require loading
doses .
Q9. A patient with hepatic impairment is prescribed a drug metabolized
by CYP2C19. The PMHNP should anticipate:
• A) Decreased drug half-life
